Miriam Kidron's most recent trade in Oramed Pharmaceuticals, Inc was a trade of 19,000 Performance Stock Units done . Disclosure was reported to the exchange on Jan. 22, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 19,000 | 0 | - | - | Performance Stock Units | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 19,000 | 1,448,664 (8%) | 0% | 0 | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Jan 2026 | 86,166 | 1,343,498 (7%) | 0% | 0 | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 121,331 | 1,314,664 (7%) | 0% | 0 | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 115,000 | 1,429,664 (8%) | 0% | 0 | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 19,000 | 19,000 | - | - | Performance Stock Units | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 74,000 | 1,074,666 (6%) | 0% | 0 | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 66,667 | 1,193,333 (6%) | 0% | 0 | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 52,000 | 1,126,666 (6%) | 0% | 0 | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 207,000 | 1,000,666 (5%) | 1% | - | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 30,000 | 793,666 (4%) | 0% | - | Common Stock | |
| Oramed Pharma Inc | Kidron Miriam | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 295,500 | 763,666 (4%) | 1% | - | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 53,500 | 468,166 (2%) | 0% | - | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 213,000 | 414,666 (2%) | 1% | - | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 2.01 per share. | 14 Mar 2023 | 100,000 | 201,666 (1%) | 0% | 2.0 | 201,000 | Common Stock |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 84,000 | 301,666 (1%) | 0% | - | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 34,000 | 217,666 (1%) | 0% | - | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 72,000 | 72,000 | - | - | Stock Option (right to buy) | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 42,000 | 183,666 (1%) | 0% | - | Common Stock | |
| Oramed Pharma Inc | Miriam Kidron | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2021 | 66,666 | 141,666 (0%) | 0% | - | Common Stock |